The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial

Pharmacogenomics Journal

Volumn 4, Issue 3, 2004, Pages 184-192

  Lerman, C ^a,b   Wileyto, E P ^a   Patterson, F ^a   Rukstalis, M ^a   Audrain McGovern, J ^a   Restine, S ^a   Shields, P G ^c   Kaufmann, V ^a   Redden, D ^d   Benowitz, N ^e   Berrettini, W H ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Genetic; Mu opioid receptor; Nicotine dependence; Treatment

Indexed keywords

ASPARAGINE; ASPARTIC ACID; MU OPIATE RECEPTOR; NICOTINE; NOSE SPRAY;

ADULT; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; NICOTINE REPLACEMENT THERAPY; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SMOKING; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; WEIGHT GAIN;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRANASAL; ADULT; ASPARAGINE; ASPARTIC ACID; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NICOTINE; PREDICTIVE VALUE OF TESTS; RECEPTORS, OPIOID, MU; SMOKING; TIME FACTORS; VARIATION (GENETICS);

EID: 2942738811     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500238     Document Type: Article

References (57)

1. USPHS. A clinical practice guideline for treating tobacco use and dependence. JAMA 2000; 283: 3244-3254.
2. Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation: six-month results from two multicenter controlled trials. JAMA 1991; 266: 3133-3138.
3. Fiore M, Smith S, Jorenby D, Baker T. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA 1994; 271: 1940-1947.
4. Zadina JE, Hackler L, Ge LJ, Kastin AJ. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 1997; 386: 499-502.
5. Boyadjieva NI, Sarkar DK. The secretary response of hypothalamic beta-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal. Life Sci 1997; 61: PL59-66.
6. Davenport KE, Houdi AA, Van Loon GR. Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci Lett 1990; 113: 40-46.
7. Bond LaForge K et al. Single nucleotide polymorphism in the human mu opioid receptor gene alters Beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 1998; 95: 9608-9613.
8. Gelernter J, Kranzler H, Cubells J. Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol Psychiatry 1999; 4: 476-483.
9. Crowley JJ et al. A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr Genet 2003; 13: 169-173.
10. Henningfield J, Keenan R. Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 1993; 61: 743-750.
11. Henningfield J. Nicotine medications for smoking cessation. N Engl J Med 1995; 333: 1196-1203.
12. Hughes J. Pharmacotherapy for smoking cessation: unvalidated assumptions, anomalies, and suggestions for future research. J Consult Clin Psychol 1993; 61: 751-760.
13. Johansson CJ, Olsson P, Bende M, Carlsson T, Gunnarsson PO. Absolute bioavailability of nicotine applied to different nasal regions. Eur J Clin Pharmacol 1991; 41: 585-588.
14. Benowitz N. Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol 1996; 36: 597-613.
15. Oslin DW et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28: 1546-1552.
16. Silagy C, Mant D, Fowler G, Lodge M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 343: 139-142.
17. Tonnesen P, Norregaard J, Simonsen K, Sawe U. A double-blind trial of a 16-h transdermal nicotine patch in smoking cessation. N Engl J Med 1991; 325: 311-315.
18. Hjalmarson A, Franzon M, Westin A, Wiklund O. Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study. Arch Intern Med 1994; 154: 2567-2572.
19. Wetter D et al. Gender differences in smoking cessation. J Counsel Clin Psychol 1999; 67: 555-562.
20. Lerman C et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 2003.
21. Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet 2003; 361: 598-604.
22. Pritchard J, Rosenberg N. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999; 65: 220-228.
23. Hurt RD et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. JAMA 1994; 271: 595-600.
24. Sachs DP, Sawe U, Leischow SJ. Effectiveness of a 16-h transdermal nicotine patch in a medical practice setting, without intensive group counseling. Arch Intern Med 1993; 153: 1881-1890.
25. Lerman C et al. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend 2002; 67: 219-223.
26. Gu DF, Hinks LJ, Morton NE, Day IN. The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann Hum Genet 2000; 64: 383-390.
27. Lerman C et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 2002; 12: 627-634.
28. Lerman C et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 2003; 22: 541-548.
29. Houdi AA, Pierzchala K, Marson L, Palkovits M, Van Loon GR. Nicotine-induced alteration in Tyr-Gly-Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides 1991; 12: 161-166.
30. Pierzchala K, Houdi AA, Van Loon GR. Nicotine-induced alterations in brain regional concentrations of native and cryptic Met- and Leu-enkephalin. Peptides 1987; 8: 1035-1043.
31. Wewers ME, Tejwani GA, Anderson J. Plasma nicotine, plasma beta-endorphin and mood states during periods of chronic smoking, abstinence and nicotine replacement. Psychopharmocology (Berl) 1994; 116: 98-102.
32. Gilbert DG, Meliska CJ, Plath LC. Noise stress does not modulate effects of smoking/nicotine on beta-endorphin, cortisol, ACTH, glucose, and mood. Psychophormacology (Berl) 1997; 130: 197-202.
33. Pomerleau OF, Fertig JB, Seyler LE, Jaffe J. Neuroendocrine reactivity to nicotine in smokers. Psychopharmacology (Berl) 1983; 81: 61-67.
34. Spanagel R, Herz A, Bals-Kubik R, Shippenberg TS. Beta-endorphin-induced locomotor stimulation and reinforcement are associated with an increase in dopamine release in the nucleus accumbens. Psychopharmacology (Berl) 1991; 104: 51-56.
35. Low MJ, Hayward MD, Appleyard SM, Rubinstein M. State-dependent modulation of feeding behavior by proopiomelanocortin-derived beta-endorphin. Ann NY Acad Sci 2003; 4: 192-201.
36. Appleyard SM et al. A role for the endogenous opioid beta-endorphin in energy homeostasis. Endocrinology 2003; 4: 1753-1760.
37. Radcliffe RA, Erwin VG. Genetic relationship between central beta-endorphin and novelty-induced locomotor activity. Pharmacol Biochem Behav 1998; 60: 709-718.
38. Jorenby D et al. Varying nicotine patch dose and type of smoking cessation counseling. JAMA 1995; 274: 1347-1352.
39. Tonnesen P et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J 1999; 13: 238-246.
40. Pomerleau OF et al. Prolonged nicotine patch use in quitters with past abstinence-induced depressed mood. J Subst Abuse Treat 2003; 24: 13-18.
41. Magura S, Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med 2001; 68: 62-74.
42. Ahluwalia JS, McNagny SE, Clark WS. Smoking cessation among inner-city African Americans using the nicotine transdermal patch. J Gen Intern Med 1998; 13: 1-8.
43. Perng RP, Hsieh WC, Chen YM, Lu CC, Chiang SJ. Randomized, double-blind, placebo-controlled study of transdermal nicotine patch for smoking cessation. J Formos Med Assoc 1998; 97: 547-551.
44. Xu C, Goodz S, Sellers EM, Tyndale RF. CYP2A6 genetic variation and potential consequences. Adv Drug Deliv Rev 2002; 54: 1245-1256.
45. Sutherland G et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992; 340: 324-329.
46. Silagy C, Mant D, Fowler G, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2001; CD000146.
47. Fiore MC et al. Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments. Chest 1994; 105: 524-533.
48. Brown R, Burgess E, Sales S, Whiteley J. Reliability and validity of a smoking timeline follow-back interview. Psychol Addictive Behav 1998; 12: 101-112.
49. Hughes JR et al. Measure of abstinence in clinical trials: issues and recommendations. Nicotine Tobacco Res 2003; 5: 13-25.
50. Ossip-Klein DJ et al. Classification and assessment of smoking behavior. Health Psychol 1986; 5(Suppl): 3-11.
51. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Soc Res Nicotine Tobacco 2001: 149-159.
52. Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. John Wiley & Sons: New York, NY 1999.
53. Lawson GM et al. Application of serum nicotine and plasma cotinine concentrations to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy. J Clin Pharmacol 1998; 38: 502-509.
54. Jacob III P, Wilson M, Benowitz NL. Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. J Chromatogr 1981; 222: 61-70.
55. Watson D, Clark L, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Personality Social Psychol 1988; 54: 1063-1070.
56. Long JC, Williams RC, Urbanek M. An E-M algorithm and testing strategy for multiple-locus haplotypes. Am J Hum Genet 1995; 56: 799-810.
57. Mander A. Haplotype analysis in population-based association studies. Stata J 2001; 1: 58-75.